Related Experiment Videos
Improved tumour localisation using indium-111 labelled antibodies.
British Medical Journal (Clinical Research Ed.)
|July 16, 1983
Summary
Indium-111 labelled antibodies targeting carcinoembryonic antigen (CEA) significantly improve tumor detection compared to iodine-131. This enhanced imaging allows for greater certainty in identifying smaller or deeper CEA-producing tumors.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunodiagnostics
Background:
- Carcinoembryonic antigen (CEA) is a tumor marker.
- Immunoglobulin G (IgG) antibodies targeting CEA are used for tumor localization.
- Radiolabeling of antibodies is crucial for imaging.
Purpose of the Study:
- To compare the efficacy of Indium-111 (111In) and Iodine-131 (131I) labeled anti-CEA IgG antibodies in locating CEA-producing tumors.
- To evaluate imaging characteristics and lesion detection rates between the two radiolabels.
Main Methods:
- Patients received anti-CEA IgG antibodies labeled with either 111In or 131I.
- Tumor detection rates and imaging quality were assessed.
- Signal-to-noise ratio and lesion accumulation over time were analyzed.
Main Results:
- 111In-anti-CEA detected 28 out of 31 tumors, outperforming conventional techniques (26/31).
- 111In-anti-CEA detected 13 tumor areas compared to 8 with 131I-anti-CEA.
- 111In provided a better signal-to-noise ratio and longer isotope accumulation in tumors.
Conclusions:
- 111In is a superior radiolabel for anti-CEA antibody imaging compared to 131I.
- Enhanced imaging with 111In-anti-CEA facilitates the detection of smaller or deeper tumors.
- This improved antibody scanning enhances diagnostic certainty in oncology.